This episode examines the FDA’s establishment of regulatory pathways for patient-facing generative AI through Breakthrough Device Designation for a post-operative chatbot, Salesforce’s deployment of pre-configured workflow agents with HealthEx, Verily, and Viz.ai for hospital bed management, and ECG-MoE’s forty percent inference time reduction using Mixture-of-Experts architecture. Coverage includes the release of SurvHTE-Bench and SpineBench validation datasets, FDA approval of Perimeter Medical’s Claire intraoperative imaging system for breast cancer surgery, RadNet’s two hundred fifteen million euro acquisition of Gleamer, Science Corp’s two hundred thirty million dollar Series C for in-house MEMS fabrication, KeyCare’s twenty-seven point four million dollar raise for Epic-integrated asynchronous care, and pharmaceutical deployment of AI to compress clinical trial timelines at Novartis, GSK, AstraZeneca, and Genmab. The briefing connects regulatory acceleration, architectural optimization, benchmark fragmentation, and trial operations automation across diagnostic imaging consolidation and neural interface manufacturing.
